Table 1 Baseline patient, donor, disease and transplant-related characteristics
Characteristics | CIC (%) N=23 | RIC (%) N=23 | P-value |
|---|---|---|---|
Median age at BMT (years) (range) | 47 (31–60) | 54 (38–74) | 0.003 |
Age at BMT | 0.003 | ||
<50 years | 16 (70) | 6 (26) | |
⩾50 years | 7 (30) | 17 (74) | |
Proportion of male patients | 18 (78) | 16 (70) | 0.50 |
PS at BMT | 0.09 | ||
<80 | 2 (9) | 3 (13) | |
⩾80 | 21 (91) | 16 (70) | |
Missing | 0 | 4 (17) | |
Myelofibrosis | 0.52 | ||
Primary | 15 (65) | 17 (74) | |
Secondary | 8 (35) | 6 (26) | |
PTMF | 8 | 5 | |
PPMF | 0 | 1 | |
Dupriez score | 0.35 | ||
Low (0) | 02 (9) | 5 (22) | |
Intermediate (1) | 14 (61) | 14 (61) | |
High (2) | 7 (30) | 04 (17) | |
Spleen at BMT | 0.42 | ||
Splenectomy | 2 (9) | 3 (13) | |
Not palpable | 2 (9) | 5 (22) | |
Enlarged | 18 (82) | 15 (65) | |
Time Dx. to BMT | 0.05 | ||
<1 year | 16 (70) | 8 (35) | |
1–3 years | 5 (21) | 8 (35) | |
>3 years | 2 (9) | 7 (30) | |
Source of stem cells | 0.0002 | ||
BM | 14 (61) | 2 (9) | |
PB | 9 (39) | 21 (91) | |
Donor | 0.77 | ||
MSD/MFD | 13 (56) | 12 (52) | |
AD | 10 (44) | 11 (48) | |
MMFD/MUD/MMUD | 2/7/1 | 0/11/0 | |
CMV status (R/D) | |||
Pos/pos or neg | 11 (48) | 11 (48) | 1.0 |
Neg/pos | 5 (22) | 5 (22) | |
Neg/neg | 7 (30) | 7 (30) | |
ABO mismatch | 0.55 | ||
No | 15 (65) | 13 (57) | |
Yes | 8 (35) | 10 (43) | |
Major/minor/bidirectional | 3/5/0 | 3/6/1 | |
Conditioning regimens | — | ||
CY+TBI | 22 (96) | — | |
Bu+CY | 1 (4) | — | |
Flu+Bu | — | 16 (70) | |
Flu+Me | — | 1 (4) | |
Flu+TBI 200 | — | 6 (26) | |
GVHD prophylaxis | 0.01 | ||
CsA+MTX | 21 (91) | 12 (52) | |
CsA+MMF | 1 (4) | 8 (36) | |
CsA alone | 1 (4) | 3 (13) | |
Serotherapy | 0.001 | ||
No | 22 (96) | 7 (30) | |
Yes | 1 (4) | 16 (70) | |
ATG/alemtuzumab | 1/0 | 14/2 | |
